Indication

As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Medicine details

Medicine name:
olaparib (Lynparza)
SMC ID:
SMC2367
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Publication due date:
09 August 2021